SAN DIEGO — In this exclusive video from Digestive Disease Week, Mark Stenhouse, president of Cologuard, discusses the non-invasive colorectal cancer screening stool test and the role it has played in increasing screening rates.
“The problem we’re trying to solve is to get more patients screened and we know that by offering patients choice, whether it’s colonoscopy or a non-invasive alternative, overall screening rates will go up,” Stenhouse told Healio Gastroenterology and Liver Disease.
Additionally, Stenhouse discussed results of a study that demonstrated that 90% of the Medicare population surveyed who completed a Cologuard (Exact Sciences) test did so within 60 days of being ordered,.
“We really see it as a complement to colonoscopy, and I think the other piece that is really important is that GIs really embrace this product,” Stenhouse said.
Editor’s note: This item has been updated to more accurately reflect the data discussed.